Zimbabwe has rejected a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' demand for sensitive biological samples.
This rejection came to light following a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesman later stated that the US was seeking biological samples for scientific study and profit while was not willing to guarantee the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued dialogue to secure a deal acceptable to both sides so the nation's critical HIV programme can continue.
Wider Background
Zimbabwe's decision follows a comparable situation in Kenya, where a high court suspended a related deal with the US after concerns were filed about the security of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and responsibility.
As per reports, Sixteen nations in Africa have so far signed these new health pacts, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information over an extended period, with no equivalent assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"In essence, our country would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our population if a future disease outbreak arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending systems already set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This system is intended to guarantee that when a country contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome continued dialogue with our American counterparts on how subsequent collaboration could be structured in a manner that honours the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but suggested that negotiations should continue given that much of the nation's HIV programmes depended on foreign aid.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group added.
The halted deal highlights the ongoing debate between accepting crucial international aid and protecting a country's data in an increasingly data-driven world.